Onco-Innovations Acquires Inka Health to Boost AI-Driven Cancer Research

Onco-Innovations Limited is pleased to announce, further to its news release dated January 22, 2025, that it has completed the acquisition of all of the outstanding share capital of Inka Health Corp, a Canadian-based software company pioneering the use of advanced AI-driven analytics and real-world multimodal data to revolutionize clinical research and drug development. In consideration for the Acquisition, Onco has issued to the former holders of the Inka Health shares an aggregate of 1,775,147 common shares of the Company ("Consideration Shares"). All of the Consideration Shares are subject to resale restrictions whereby 10% will be released and tradeable four months from the closing date of the Acquisition ("Closing Date"), 15% of the remaining Consideration Shares will be released and tradeable within six months from the Closing Date, and a further 15% of the remaining amount will be released and tradeable every six months thereafter.

By integrating Inka Health's cutting-edge AI-driven analytics and multimodal data capabilities, Onco aims to enhance its ability to accelerate cancer detection, precision oncology research, and drug development. Inka Health has developed the proprietary SynoGraph™ platform, which merges genomic, proteomic, and multimodal datasets to uncover deep insights into disease mechanisms, potentially enabling more personalized and effective treatment strategies. Inka Health's technology simulates precision-medicine clinical trials, offering the potential to significantly streamline late-stage drug discovery and clinical research by reducing both time and cost. Backed by a robust network of genomics partnerships and the expertise of Dr. Steven Jones-Head of Bioinformatics and Co-Director of the Genome Sciences Centre in Vancouver, as well as a Distinguished Scientist at the BC Cancer Research Institute¹ -Inka Health's expertise and technology is expected to strengthen Onco's capabilities in precision oncology.

Inka Health has built a strong track record of delivering innovative solutions in precision medicine, as evidenced by its partnerships with industry leaders such as AstraZeneca Canada, one of the world's largest pharmaceutical companies, and global data firm Quantify Research. These collaborations reflect Inka Health's established reputation for driving meaningful advancements in the field of science and research.

"The completion of this acquisition marks an important milestone for Onco, as it significantly enhances our ability to drive forward AI-powered precision oncology. Inka Health's cutting-edge technology and proven track record with industry leaders helps advance our capabilities in cancer therapeutic development and treatment. We are excited to integrate Inka's expertise into our operations as we continue to advance towards the next stages in the development of our technology and research," said Thomas O'Shaughnessy, CEO of Onco-Innovations.

"Joining forces with Onco-Innovations marks an exciting step forward for Inka Health. By leveraging our combined capabilities, we aim to enhance the speed and precision of cancer research, enabling the potential for developments that were previously out of reach or extremely time-consuming. Our AI-driven technology is designed to unlock deeper insights into cancer biology, and I believe that together we can push the boundaries of data-driven research, accelerate the research and development for more effective treatments, and ultimately make significant strides towards advancing the field of oncology research," said Dr. Paul Arora, CEO of Inka Health.

The Company is also pleased to announce that it has closed its previously-announced at a price of $2.45 per Unit, for aggregate gross proceeds of $1,000,000. The proceeds from the Private Placement will be used for general working capital, corporate and research and development purposes, including to continue to fund research studies, to provide funding to pursue the further development of Inka Health's AI technology, and to continue to increase market awareness of Onco and its business activities. Pursuant to applicable securities laws, all securities issued under the Private Placement will be subject to a statutory hold period of four months and one day, expiring on June 4, 2025.